REVERSIBLE NEUROLOGIC TOXICITY IN PATIENTS TREATED WITH STANDARD-DOSE FLUDARABINE PHOSPHATE FOR MYCOSIS-FUNGOIDES AND CHRONIC LYMPHOCYTIC-LEUKEMIA

被引：44

作者：

COHEN, RB ^{[1
]}

ABDALLAH, JM ^{[1
]}

GRAY, JR ^{[1
]}

FOSS, F ^{[1
]}

机构：

[1] NCI, BETHESDA, MD 20892 USA

来源：

ANNALS OF INTERNAL MEDICINE | 1993年 / 118卷 / 02期

关键词：

LEUKEMIA; LYMPHATIC; CHRONIC; MYCOSIS FUNGOIDES; FLUDARABINE PHOSPHATE; CENTRAL NERVOUS SYSTEM DISEASES; NEUROLOGIC MANIFESTATIONS;

D O I：

10.7326/0003-4819-118-2-199301150-00007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fludarabine phosphate is approved for the treatment of advanced B-cell chronic lymphocytic leukemia refractory to alkylating agents. We report two cases of disabling but reversible neurotoxicity in a patient with mycosis fungoides and a patient with chronic lymphocytic leukemia who received standard doses of fludarabine (20 to 25 mg m2 per day for 5 days) every 28 days for 6 to 8 cycles). Serial brain magnetic resonance imaging scans in the patient with mycosis fungoides showed rapid evolution of white-matter changes with subsequent complete resolution.

引用

页码：114 / 116

页数：3

共 9 条

[1]

CHUN HG, 1986, CANCER TREAT REP, V70, P1225

[2] ACTIVITY OF FLUDARABINE IN PREVIOUSLY TREATED NON-HODGKINS LOW-GRADE LYMPHOMA - RESULTS OF AN EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY [J].